LightOx is using new technologies to develop light-activated treatment which can improve outcomes for patients and reduce the need for surgery.
The investment from the Northern Accelerator Seed Investment Fund, will help the company advance clinical trials and set up new laboratories in Newcastle.
It is part of a round which includes existing investors High Force Researh and Meneldor as well new investment from New Grounds VC based in London.
Dr Sam Whitehouse, LightOx CEO, said, “Having had a challenging 18 months through the pandemic, we are delighted we have secured new investors to come alongside our existing shareholders and show how exciting our light-activated technology is and push our lead candidate towards the clinic.
“Light-activated treatment can identify and target cancer cells, particularly in the case of oral cancer this can alleviate the need for invasive surgery. It also has the potential to be used in a wide range of therapeutic indications and application areas, which we’re very keen to develop.”
Register now to continue reading
Thank you for visiting Dental Nursing and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Up to 2 free articles per month
-
New content available
Already have an account? Sign in here